High sensitivity and clonal stability of the genomic fusion as single marker for response monitoring in <i>ETV6‐RUNX1</i>‐positive acute lymphoblastic leukemia

Abstract

ETV6-RUNX1 fusion sites are highly sensitive and reliable MRD markers. Our data confirm that they are unaffected by clonal evolution and selection during front-line and second-line chemotherapy in contrast to Ig/TCR rearrangements, which require several markers per patient to compensate for the observed loss of target clones. In future studies, the genomic ETV6-RUNX1 fusion can be used as single MRD marker.